ANI PHARMACEUTICALS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M |
| Operating income | $111.1M | $584,000 | $47.0M | -$35.3M | -$39.8M |
| Cash from operations | $185.2M | $64.0M | $119.0M | -$31.2M | $3.3M |
| Capital expenditure | $13.8M | $16.2M | $8.9M | $8.9M | $2.6M |
| Free cash flow | $171.4M | $47.8M | $110.1M | -$40.1M | $765,000 |
| Share repurchases | $12.2M | $11.0M | $5.0M | $2.0M | $890,000 |
| Impairments | $767,000 | $7.6M | $0 | $574,000 | $2.4M |
| Total assets | $1.4B | $1.3B | $904.4M | $760.1M | $771.6M |
| Total liabilities | $899.7M | $855.9M | $446.8M | $421.5M | $412.9M |
Shares outstanding 22.7M · Free float 60.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.